Trump’s Health Picks Poised to Steer FDA Enforcement, Compliance

The Trump administration’s health agency nominees are likely to wade deeper into FDA enforcement authorities than typical administrations, targeting vaccines, product promotions, and drug compounding, former agency officials and health attorneys say.

The Food and Drug Administration’s powerful oversight to ensure the safety and efficacy of drugs and other products it regulates could face new pressures under President-elect Donald Trump’s health agency picks—specifically Robert F. Kennedy Jr. as health secretary and Johns Hopkins surgeon Marty Makary as FDA chief.

“The secretary is the boss, it is his authority. At some point, he can reach in,” said Jeremy Sharp, ...